Search

Your search keyword '"Guay J"' showing total 545 results
Start Over Author "Guay J"
545 results on '"Guay J"'

51. Management of antiplatelet therapy in patients undergoing elective invasive procedures: Proposals from the French Working Group on perioperative hemostasis (GIHP) and the French Study Group on thrombosis and hemostasis (GFHT). In collaboration with the French Society for Anesthesia and Intensive Care (SFAR)

Author

Godier, Anne, primary, Fontana, Pierre, additional, Motte, Serge, additional, Steib, Annick, additional, Bonhomme, Fanny, additional, Schlumberger, Sylvie, additional, Lecompte, Thomas, additional, Rosencher, Nadia, additional, Susen, Sophie, additional, Vincentelli, André, additional, Gruel, Yves, additional, Albaladejo, Pierre, additional, Collet, Jean-Philippe, additional, Albaladejo, P., additional, Belisle, S., additional, Blais, N., additional, Bonhomme, F., additional, Borel-Derlon, A., additional, Borg, J.Y., additional, Bosson, J.-L., additional, Cohen, A., additional, Collet, J.-P., additional, de Maistre, E., additional, Faraoni, D., additional, Fontana, P., additional, Garrigue Huet, D., additional, Godier, A., additional, Gruel, Y., additional, Guay, J., additional, Hardy, J.F., additional, Huet, Y., additional, Ickx, B., additional, Laporte, S., additional, Lasne, D., additional, Levy, J.H., additional, Llau, J., additional, Le Gal, G., additional, Lecompte, T., additional, Lessire, S., additional, Longrois, D., additional, Madi-Jebara, S., additional, Marret, E., additional, Mas, J.L., additional, Mazighi, M., additional, Mismetti, P., additional, Morange, P.E., additional, Motte, S., additional, Mullier, F., additional, Nathan, N., additional, Nguyen, P., additional, Ozier, Y., additional, Pernod, G., additional, Rosencher, N., additional, Roullet, S., additional, Roy, P.M., additional, Samama, C.M., additional, Schlumberger, S., additional, Schved, J.F., additional, Sié, P., additional, Steib, A., additional, Susen, S., additional, van Belle, E., additional, van Der Linden, P., additional, Vincentelli, A., additional, and Zufferey, P., additional

Published
2018
Full Text
View/download PDF

54. The discovery of rofecoxib, [MK 966, VIOXX ®, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5 H)-furanone], an orally active cyclooxygenase-2 inhibitor

Author

Prasit, P, Wang, Z, Brideau, C, Chan, C.-C, Charleson, S, Cromlish, W, Ethier, D, Evans, J.F, Ford-Hutchinson, A.W, Gauthier, J.Y, Gordon, R, Guay, J, Gresser, M, Kargman, S, Kennedy, B, Leblanc, Y, Léger, S, Mancini, J, O'Neill, G.P, Ouellet, M, Percival, M.D, Perrier, H, Riendeau, D, Rodger, I, Tagari, P, Thérien, M, Vickers, P, Wong, E, Xu, L.-J, Young, R.N, Zamboni, R, Boyce, S, Rupniak, N, Forrest, M, Visco, D, and Patrick, D

Published
1999
Full Text
View/download PDF

60. Angular and Linear Comparisons With Unilateral Mandibular Asymmetry.

Author

Tallents, R. H., Guay, J. A., Katzberg, R. W., Murphy, W., and Proskin, H.

Subjects
TEMPOROMANDIBULAR joint abnormalities, HYPERPLASIA, SYMMETRY (Biology), CYTODIAGNOSIS, PATHOLOGY
Abstract

Copyright of Journal of Craniomandibular Disorders is the property of Quintessence Publishing Company Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
1991

61. Gestion des agents antiplaquettaires en cas de procédure invasive non programmée ou d’hémorragie. Propositions du Groupe d’intérêt en hémostase périopératoire (GIHP) et du Groupe français d’études sur l’hémostase et la thrombose (GFHT) en collaboration avec la Société française d’anesthésie et de réanimation (SFAR)

Author

Godier, Anne, Garrigue, Delphine, Lasne, Dominique, Fontana, Pierre, Bonhomme, Fanny, Collet, Jean-Philippe, de Maistre, Emmanuel, Ickx, Brigitte, Gruel, Yves, Mazighi, Mikael, Nguyen, Philippe, Vincentelli, André, Albaladejo, Pierre, Lecompte, Thomas, Belisle, S., Blais, N., Borel-Derlon, A., Borg, J.Y., Bosson, J.-L., Cohen, A., Faraoni, D., Garrigue Huet, D., Guay, J., Hardy, J.F., Huet, Y., Laporte, S., Levy, J.H., Llau, J., Le Gal, G., Lessire, S., Longrois, D., Madi-Jebara, S., Marret, E., Mas, J.L., Meyer, G., Mismetti, P., Morange, P.E., Motte, S., Mullier, F., Nathan, N., Ozier, Y., Pernod, G., Rosencher, N., Roullet, S., Roy, P.M., Samama, C.M., Schlumberger, S., Schved, J.F., Sié, P., Steib, A., Susen, S., van Belle, E., van Der Linden, P., and Zufferey, P.

Abstract

Le Groupe d’intérêt en hémostase périopératoire (GIHP) et le Groupe français d’études sur l’hémostase et la thrombose (GFHT) en collaboration avec la Société française d’anesthésie et de réanimation (SFAR) ont fait des propositions sur la gestion des agents antiplaquettaires (AAP) en cas de procédure invasive non programmée ou d’hémorragie. Ces propositions ont été discutées puis validées par un vote, elles font toutes l’objet d’un accord fort. La gestion des AAP en urgence nécessite de prendre en compte leurs caractéristiques pharmacocinétiques et pharmacodynamiques, d’évaluer l’affaiblissement de la compétence hémostatique liée aux AAP et le risque hémorragique qu’il entraîne. Les tests fonctionnels plaquettaires peuvent aider à cette évaluation. Lorsque le risque hémorragique lié aux AAP est susceptible d’aggraver le pronostic, la neutralisation des AAP doit être envisagée, en prenant en compte l’efficacité des moyens de neutralisation (qui sont limités pour le prasugrel et le ticagrelor) mais aussi les risques associés à ces moyens. Ceux-ci incluent la transfusion plaquettaire, à des doses adaptées à l’AAP considéré, et les agents hémostatiques (facteur VII activé recombinant et acide tranexamique). Pour les procédures invasives non programmées, le report de quelques jours, voire de quelques heures, doit être envisagé lorsqu’il ne compromet pas le pronostic vital ou fonctionnel du patient, jusqu’à élimination ou diminution suffisante de l’effet de l’AAP ou de son métabolite actif.

Published
2024
Full Text
View/download PDF

65. Abstracts

Author

Crosby, E. T., Halpern, S., Bill, K. M., Flynnn, R. J., Moore, J., Navaneelan, C., Cunningham, A., Yu, P. Y. H., Gamling, D. R., McMorland, G. H., Perreault, C., Guay, J., Gaudreault, P., Hollman, C., Meloche, R., Hackman, T., Sheps, S. B., Murray, W. B., Heiman, P. A., Slinger, P., Triolet, W., Jain, U., Rao, T. L. K., Dasari, M., Pifarre, R., Sullivan, H., Calandra, D., Friesen, R. M., Bjornson, J., Hatton, G., Parlow, J. L., Casey, W. F., Broadman, L. M., Rice, L. J., Dailey, M., Andrews, W. R., Stigi, S., Jendrek, V., Shevde, K., Withington, D. E., Saoud, A. Tazi, Ramsay, J. G., Bilodeau, J., Johnson, D., Mayers, I., Doran, R. J., Wong, P. Y., Mullen, Brendan J., Wigglesworth, D., Byrick, R. J., Kay, J. Colin, Stubbing, J. F., Sweeney, B. P., Dagher, E., Dumont, L., Lagace, G., Chartrand, C., Badner, N. H., Sandier, A. N., Leitch, L., Koren, G., Erian, R. F., Bunegin, L., Shulman, D. L., Burrows, F., O’Sullivan, K., Bouchier, D., Kashin, B. A., Wynands, J. E., Villeneuve, E., Blaise, G., Guerrard, M. J., Buluran, J., Effa, E., Vaghadia, H., Jenkins, L. C., Janisse, T., Scudamore, C. H., Patel, P. M., Mutch, W. A. C., Ruta, T. S., McNeill, B. R., Murkin, J. M., Gelb, A. W., Farrar, J. K., Johnson, G. D., Adams, M. A., Lillicrap, D. P., Lindblad, T., Beattie, W. S., Buckley, D. N., Forrest, J. B., Lessard, M. R., Trépanier, C. A., Baribault, J. P., Brochu, J. G., Brousseau, C. A., Cote, J. J., Denault, P., Whang, P., Moudgil, G. C., Daly, N., Morrison, D. H., Ogilvie, R., Man, J., Ehler, T., Leitch, L. F., Dupuis, J. Y., Martin, R., Tessonnier, J. M., Barry, A. W., Milne, B., Quintin, L., Gillon, J. Y., Pujol, J. F., DeMonte, F., Zhang, C., Hamilton, J. T., Zhou, Y., Plourde, G., Picton, T. W., Kellett, A., Pilato, M. A., Bissonnette, B., Lerman, J., Brown, K. A., Dundee, J. W., Sosis, M., Dillon, F., Stetson, J. B., Voorhees, W. D., Bourland, J. D., Geddes, L. A., Shoenlein, W. E., O’Leary, G., Teasdale, S., Knill, R. L., Rose, E. A., Berko, S. L., Smith, C. E., Sadler, J. M., Bevan, J. C., Donati, F., Bevan, D. R., Tellez, J., Turner, D., Kao, Y. J., Salidivia, V., Roldan, L., Orrego, H., Carmicheal, F. J., Kent, A. P., Parker, C. J. R., Hunter, J. M., Finley, G. A., Goresky, G. V., Klassen, K., McDiarmid, C., Shaffer, E., Vaughan, M., Randolph, J., Szalados, J. E., Lazzell, V. A., Creighton, R. E., Poon, A. O., Mclntyre, B., Douglas, M. J., Swenerton, J. E., Farquharson, D. F., Landry, D., Petit, F., Riegert, D., Koch, J. P., Maggisano, R., Devitt, J. H., Jense, H. G., Dubin, S. A., Silverstein, P. I., Rodriguez, N., Wakefield, M. L., Williams, R., Dubin, S., Smith, J. J., Hofmann, V. C., Jarvis, A. P., Forbes, R. B., Murray, D. J., Dillman, J. B., Dull, D. L., Cohen, M. M., Cameron, C. B., Johnston, R. G., Konopad, E., Jivraj, K., Hunt, D., Eastley, R., Strunin, L., Fairbrass, M. J., Laganiere, S., McGilvery, M., Foster, B., Young, P., Weisel, D., Parra, L., Suarez Isla, B. A., Lopez, J. R., Hall, R. I., Hawwa, R., Kashtan, H., Edelist, G., Mallon, J., Kapala, D., Dhamee, M. Saeed, Reynolds, A. C., Olund, T., Entress, J., Kalbfleisch, J., Bell, S. D., Goldberg, M. E., Bracey, B. J., Goldhill, D. R., Bennett, M. H., Emmott, R. S., Innis, R. F., Yate, P. M., Flynn, P. J., Gill, S. S., Saunders, P. R., Geisecke, A. H., Feldman, J. M., Banner, M. J., Siriwardhana, S. A., Kawas, A., Lipton, J. L., Giesecke, A. H., Doyle, D. J., Volgyesi, G. A., Hillier, S. C., Gallagher, J., Hargaden, K., Hamil, M., Cunningham, A. J., Scott, W. A. C., Sielecka, D., Illing, L. H., Jani, K., Scarr, M., Maltby, J. R., Roy, J., McNulty, S. E., Torjman, M., Carey, C., Bracey, B., Markham, K., Durcan, J., Blackstock, D., DaSilva, C. A., Demars, P. D., Montgomery, C. J., Steward, D. J., Sessler, D. I., Laflamme, P., McDevitt, S., Kamal, G. D., Symreng, T., Tatman, D. J., Durcharme, J., Varin, F., Besner, J. G., Dyck, J. B., Chung, F., Arellano, R., Lim, G., Bailey, D. G., Bayliff, C. D., Cunningham, D. G., Ewen, A., Sheppard, S. D., Mahoney, L. T., Bacon, G. S., Rice, L. R., Newman, K., Loe, W., Toth, M., Pilato, M., Classen, K., McDiamid, C., Burrows, F. A., Irish, C. L., Casey, W., Hauser, G. J., Chan, M. M., Midgley, F. M., Holbrook, P. R., Elliott, M. E., Man, W. K., Finegan, B. A., Clanachan, A. S., Hudson, R. J., Thomson, I. R., Burgess, P. M., Rosenbloom, M., Fisher, J. M., O’Connor, J. P., Ralley, F. E., Robbins, G. R., Moote, C. A., Manninen, P. H., English, M., Farmer, C., Scott, A., White, I. W. C., Biehl, D., Donen, N., Mansfield, J., Cohen, M., Wade, J. G., Woodward, C., Ducharme, J., Gerardi, A., Mijares, A., Code, W. E., Hertz, L., Chung, A., Meier, H. M. R., Lautenschlaeger, E., Seyone, C., Wassef, M. R., Devitt, F. H., Cheng, D. C. H., Dyck, B., Chan, V. W. S., Ferrante, F. M., Arthur, G. R., Rice, L., Annallah, R. H., Etches, R. C., Loulmet, D., Lacombe, P., Hollmann, C., Tanguay, M., Blaise, G. A., Lenis, S. G., Fear, D. W., Lang, S. A., Ha, H. C., Germain, H., Neion, A., Dorian, P., Salter, D., Pollick, C., Cervenko, F., Parlow, J., Pym, J., Nakatsu, K., Elliott, D., Miller, D. R., Martineau, R. J., Ewing, D., Martineau, R. J., Knox, J. W. D., Oxorn, D. C., O’Connor, J. P., Whalley, D. G., Rogers, K. H., Kay, J. C., Mazer, C. D., Belo, S. E., Hew-Wing, P., Hew, E., Tessonier, J. M., Thibault, G., Testaert, E., Chartrand, D., Cusson, J. R., Kuchel, O., Larochelle, P., and Couture, J.

Published
1989
Full Text
View/download PDF

66. Quelle pertinence pour l’évaluation standardisée des distorsions cognitives en délinquance sexuelle? Présentation, Illustrations, Limites, et Perspectives

Author

Benbouriche, Massil, Vanderstukken, Olivier, Guay, J.-P., Testé, Benoît, Renaud, Patrice, Centre de Recherches en Psychologie Cognition et Communication (CRPCC EA 1285), Université de Bretagne Sud (UBS)-Université de Brest (UBO)-MEN : EA1285-Université de Rennes 2 (UR2), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Institut national supérieur de formation et de recherche pour l'éducation des jeunes handicapés et les enseignements adaptés (INSHEA), and Leroux, Laurence

Subjects
[SHS.PSY] Humanities and Social Sciences/Psychology, Méthode psychométrique, [SHS.PSY]Humanities and Social Sciences/Psychology, [SHS] Humanities and Social Sciences, Agression sexuelle, Distorsions cognitives, Évaluation standardisée, Recension, [SHS]Humanities and Social Sciences
Abstract

International audience; With regard to the importance of cognitive distortions in child molesting, it remains critical to be able to assess cognitive distortions. To this purpose, the Abel and Becker Cognition Scale (Abel al., 1989) and the Molest Scale (Bumby, 1996) are commonly used. Through a review of standardized assessment of cognitive distortions, different limits regarding psychometrics properties and questionnaires’ validity arise doubts about psychometric method’s relevance. Implication and prospects are discussed. Key-Words: Cognitive distortions; Child molesters; Standardized assessment; Psychometrics; Review. Résumé Au regard de l’importance accordée aux distorsions cognitives dans l’agression sexuelle sur enfant, disposer d’une évaluation standardisée des distorsions cognitives constitue un enjeu majeur. À cet égard, l’Abel and Becker Cognition Scale (Abel et al., 1989) et la Molest Scale (Bumby, 1996) sont les instruments les plus communément utilisés. Rejoignant les données de littérature internationale, cet article participe toutefois à entretenir un doute raisonnable quant à la pertinence de l’évaluation standardisée et le recours à des mesures auto-rapportées pour l’étude des distorsions cognitives en délinquance sexuelle. Les implications et les perspectives pour de futures recherches sont discutées.

Published
2013

70. Worst-case scenario SBAS interference

Author

Lestarquit, Laurent, Issler, Jean-Luc, Nouvel, Olivier, Sihrener, Matthieu, Lamontagne, Guillaume, guay, J C, Landry, René, Julien, Olivier, Macabiau, Christophe, Nouvel-Malicorne, Marie, Centre National d'Études Spatiales [Toulouse] (CNES), M3 Systems, Ecole de Technologie Supérieure [Montréal] (ETS), ENAC Equipe TELECOM-SIGNAV (SIGNAV), ENAC - Equipe télécommunications (TELECOM), Ecole Nationale de l'Aviation Civile (ENAC)-Ecole Nationale de l'Aviation Civile (ENAC), and Ecole Nationale de l'Aviation Civile (ENAC)

Subjects
[SPI.SIGNAL]Engineering Sciences [physics]/Signal and Image processing, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2009

71. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor

Author

Riendeau, D, Percival, M D, Boyce, S, Brideau, C, Charleson, S, Cromlish, W, Ethier, D, Evans, J, Falgueyret, J -P, Ford-Hutchinson, A W, Gordon, R, Greig, G, Gresser, M, Guay, J, Kargman, S, Léger, S, Mancini, J A, O'Neill, G, Ouellet, M, Rodger, I W, Thérien, M, Wang, Z, Webb, J K, Wong, E, Xu, L, Young, R N, Zamboni, R, Prasit, P, and Chan, C -C

Subjects
Lipopolysaccharides, Male, Fever, Indomethacin, Administration, Oral, CHO Cells, Transfection, Dinoprostone, Rats, Sprague-Dawley, Structure-Activity Relationship, Cricetinae, Animals, Edema, Humans, Cyclooxygenase Inhibitors, Furans, Saimiri, Cyclooxygenase 2 Inhibitors, Dose-Response Relationship, Drug, Anti-Inflammatory Agents, Non-Steroidal, Membrane Proteins, Recombinant Proteins, Rats, Isoenzymes, Thromboxane B2, Peroxidases, Cyclooxygenase 2, Hyperalgesia, Prostaglandin-Endoperoxide Synthases, Papers, Cyclooxygenase 1, Digestive System
Abstract

1. DFU (5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl)phenyl-2(5H)-furan one) was identified as a novel orally active and highly selective cyclo-oxygenase-2 (COX-2) inhibitor. 2. In CHO cells stably transfected with human COX isozymes, DFU inhibited the arachidonic acid-dependent production of prostaglandin E2 (PGE2) with at least a 1,000 fold selectivity for COX-2 (IC50 = 41 +/- 14 nM) over COX-1 (IC5050 microM). Indomethacin was a potent inhibitor of both COX-1 (IC50 = 18 +/- 3 nM) and COX-2 (IC50 = 26 +/- 6 nM) under the same assay conditions. The large increase in selectivity of DFU over indomethacin was also observed in COX-1 mediated production of thromboxane B2 (TXB2) by Ca2+ ionophore-challenged human platelets (IC5050 microM and 4.1 +/- 1.7 nM, respectively). 3. DFU caused a time-dependent inhibition of purified recombinant human COX-2 with a Ki, value of 140 +/- 68 microM for the initial reversible binding to enzyme and a kappa 2 value of 0.11 +/- 0.06 s-1 for the first order rate constant for formation of a tightly bound enzyme-inhibitor complex. Comparable values of 62 +/- 26 microM and 0.06 +/- 0.01 s-1, respectively, were obtained for indomethacin. The enzyme-inhibitor complex was found to have a 1:1 stoichiometry and to dissociate only very slowly (t1/2 = 1-3 h) with recovery of intact inhibitor and active enzyme. The time-dependent inhibition by DFU was decreased by co-incubation with arachidonic acid under non-turnover conditions, consistent with reversible competitive inhibition at the COX active site. 4. Inhibition of purified recombinant human COX-1 by DFU was very weak and observed only at low concentrations of substrate (IC50 = 63 +/- 5 microM at 0.1 microM arachidonic acid). In contrast to COX-2, inhibition was time-independent and rapidly reversible. These data are consistent with a reversible competitive inhibition of COX-1. 5. DFU inhibited lipopolysaccharide (LPS)-induced PGE2 production (COX-2) in a human whole blood assay with a potency (IC50 = 0.28 +/- 0.04 microM) similar to indomethacin (IC50 = 0.68 +/- 0.17 microM). In contrast, DFU was at least 500 times less potent (IC5097 microM) than indomethacin at inhibiting coagulation-induced TXB2 production (COX-1) (IC50 = 0.19 +/- 0.02 microM). 6. In a sensitive assay with U937 cell microsomes at a low arachidonic acid concentration (0.1 microM), DFU inhibited COX-1 with an IC50 value of 13 +/- 2 microM as compared to 20 +/- 1 nM for indomethacin. CGP 28238, etodolac and SC-58125 were about 10 times more potent inhibitors of COX-1 than DFU. The order of potency of various inhibitors was diclofenacindomethacin approximately naproxennimesulide approximately meloxicam approximately piroxicamNS-398 approximately SC-57666SC-58125CGP 28238 approximately etodolacL-745,337DFU. 7. DFU inhibited dose-dependently both the carrageenan-induced rat paw oedema (ED50 of 1.1 mg kg-1 vs 2.0 mg kg-1 for indomethacin) and hyperalgesia (ED50 of 0.95 mg kg-1 vs 1.5 mg kg-1 for indomethacin). The compound was also effective at reversing LPS-induced pyrexia in rats (ED50 = 0.76 mg kg-1 vs 1.1 mg kg-1 for indomethacin). 8. In a sensitive model in which 51Cr faecal excretion was used to assess the integrity of the gastrointestinal tract in rats, no significant effect was detected after oral administration of DFU (100 mg kg-1, b.i.d.) for 5 days, whereas chromium leakage was observed with lower doses of diclofenac (3 mg kg-1), meloxicam (3 mg kg-1) or etodolac (10-30 mg kg-1). A 5 day administration of DFU in squirrel monkeys (100 mg kg-1) did not affect chromium leakage in contrast to diclofenac (1 mg kg-1) or naproxen (5 mg kg-1). 9. The results indicate that COX-1 inhibitory effects can be detected for all selective COX-2 inhibitors tested by use of a sensitive assay at low substrate concentration. The novel inhibitor DFU shows the lowest inhibitory potency against COX-1, a consistent high selectivity of inhibition of COX-2 over COX-1 (300 fold) with enzyme, whole cell and whole blood assays, with no detectable loss of integrity of the gastrointestinal tract at doses200 fold higher than efficacious doses in models of inflammation, pyresis and hyperalgesia. These results provide further evidence that prostanoids derived from COX-1 activity are not important in acute inflammatory responses and that a high therapeutic index of anti-inflammatory effect to gastropathy can be achieved with a selective COX-2 inhibitor.

Published
1997

82. ChemInform Abstract: Substituted Thiopyrano(2,3,4-c,d)indoles as Potent, Selective, and Orally Active Inhibitors of 5-Lipoxygenase. Synthesis and Biological Evaluation of L-691,816.

Author

HUTCHINSON, J. H., primary, RIENDEAU, D., additional, BRIDEAU, C., additional, CHAN, C., additional, DELORME, D., additional, DENIS, D., additional, FALGUEYRET, J.-P., additional, FORTIN, R., additional, GUAY, J., additional, HAMEL, P., additional, JONES, T. R., additional, MACDONALD, D., additional, MCFARLANE, C. S., additional, PIECHUTA, H., additional, SCHEIGETZ, J., additional, TAGARI, P., additional, THERIEN, M., additional, and GIRARD, Y., additional

Published
2010
Full Text
View/download PDF

89. Laser-written colours on silver: optical effect of alumina coating

Author

Guay Jean-Michel, Calà Lesina Antonino, Killaire Graham, Gordon Peter G., Hahn Choloong, Barry Sean T., Ramunno Lora, Berini Pierre, and Weck Arnaud

Subjects
plasmonic colouring, nanostructures, thin films, colour sensors, computional nanophotonics, Physics, QC1-999
Abstract

In this paper we discuss the optical response of laser-written plasmonic colours on silver coated via the atomic layer deposition of alumina. These colours are due to nanoparticles distributed on a flat surface and on a surface with periodic topographical features (i.e. ripples). The colours are observed to shift with increasing alumina film thickness. The colours produced by surfaces with ripples recover their original vibrancy and hue after the deposition of film of thickness ~60 nm, while colours arising from flat surfaces gradually fade and never recover. Analysis of the surfaces identifies periodic topographical features to be responsible for this behaviour. Finite-difference time-domain simulations unravel the role played by the alumina thickness in colour formation and confirm the rotations and recovery of colours for increasing alumina thickness. The coloured surfaces were evaluated for applications in colourimetric and radiometric sensing showing large sensitivities of up to 3.06/nm and 3.19 nm/nm, respectively. The colourimetric and radiometric sensitivities are observed to be colour dependent.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results